These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 32271235)

  • 1. The relationship between fibrinogen-to-albumin ratio and in-stent restenosis in patients with coronary artery disease undergoing drug-eluting stenting.
    Chen T; Sun JL; Zhang J
    Coron Artery Dis; 2020 Nov; 31(7):586-589. PubMed ID: 32271235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of red blood cell distribution in predicting drug-eluting stent restenosis in patients with stable angina pectoris after coronary stenting.
    Zhao K; Li YJ; Gao S
    Coron Artery Dis; 2015 May; 26(3):220-4. PubMed ID: 25647458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of insulin resistance on in-stent restenosis in patients undergoing coronary drug-eluting stent implantation after long-term angiographic follow-up.
    Zhao LP; Xu WT; Wang L; Li H; Shao CL; Gu HB; Chan SP; Xu HF; Yang XJ
    Coron Artery Dis; 2015 Jan; 26(1):5-10. PubMed ID: 25211654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of coronary anatomy and stenting technique on long-term outcome after drug-eluting stent implantation for unprotected left main coronary artery disease.
    Tiroch K; Mehilli J; Byrne RA; Schulz S; Massberg S; Laugwitz KL; Vorpahl M; Seyfarth M; Kastrati A;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):29-36. PubMed ID: 24332416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between uric acid to albumin ratio and in-stent restenosis in patients with coronary artery disease undergoing drug-eluting stenting.
    Liu W; Ding K; Bao J; Hu Y; Gui Y; Ye L; Wang L
    Coron Artery Dis; 2023 Dec; 34(8):589-594. PubMed ID: 37855441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for revascularization and in-stent restenosis in patients with triple-vessel disease after second-generation drug-eluting stent implantation: a retrospective analysis.
    Zeng M; Yan X; Wu W
    BMC Cardiovasc Disord; 2021 Sep; 21(1):446. PubMed ID: 34535088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and risk factors of in-stent restenosis after percutaneous coronary intervention in patients from southern China.
    Li M; Hou J; Gu X; Weng R; Zhong Z; Liu S
    Eur J Med Res; 2022 Jan; 27(1):12. PubMed ID: 35065663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Independent predictors of in-stent restenosis after drug-eluting stent implantation for ostial right coronary artery lesions.
    Watanabe Y; Takagi K; Naganuma T; Kawamoto H; Fujino Y; Ishiguro H; Tahara S; Kurita N; Hosawa K; Nakamura S; Nakamura S
    Int J Cardiol; 2017 Aug; 240():108-113. PubMed ID: 28476515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remnant Lipoprotein Cholesterol Independently Associates With In-Stent Restenosis After Drug-Eluting Stenting for Coronary Artery Disease.
    Xu X; Pandit RU; Han L; Li Y; Guo X
    Angiology; 2019 Oct; 70(9):853-859. PubMed ID: 31167539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of diabetes mellitus on long-term outcomes after repeat drug-eluting stent implantation for in-stent restenosis.
    Zhao L; Zhu W; Zhang X; He D; Guo C
    BMC Cardiovasc Disord; 2017 Jan; 17(1):16. PubMed ID: 28061808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coronary CT angiography-derived quantitative markers for predicting in-stent restenosis.
    Tesche C; De Cecco CN; Vliegenthart R; Duguay TM; Stubenrauch AC; Rosenberg RD; Varga-Szemes A; Bayer RR; Yang J; Ebersberger U; Baquet M; Jochheim D; Hoffmann E; Steinberg DH; Chiaramida SA; Schoepf UJ
    J Cardiovasc Comput Tomogr; 2016; 10(5):377-83. PubMed ID: 27431607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistant in-stent restenosis in the drug eluting stent era.
    Theodoropoulos K; Mennuni MG; Dangas GD; Meelu OA; Bansilal S; Baber U; Sartori S; Kovacic JC; Moreno PR; Sharma SK; Mehran R; Kini AS
    Catheter Cardiovasc Interv; 2016 Nov; 88(5):777-785. PubMed ID: 27184223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of coronary collateral circulation on angiographic in-stent restenosis in patients with stable coronary artery disease and chronic total occlusion.
    Yang ZK; Shen Y; Hu J; Zhang Q; Ding FH; Zhang RY; Lu L; Shen WF
    Int J Cardiol; 2017 Jan; 227():485-489. PubMed ID: 27836292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of increased serum CTRP5 levels with in-stent restenosis after coronary drug-eluting stent implantation: CTRP5 promoting inflammation, migration and proliferation in vascular smooth muscle cells.
    Shen Y; Li C; Zhang RY; Zhang Q; Shen WF; Ding FH; Lu L
    Int J Cardiol; 2017 Feb; 228():129-136. PubMed ID: 27863353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree, and independently predicts in-stent restenosis risk in coronary heart disease patients underwent drug-eluting-stent PCI.
    Song T; Fu Y; Wang Y; Li W; Zhao J; Wang X; Wang H; Zhao Y; Fu X
    BMC Cardiovasc Disord; 2021 Jan; 21(1):24. PubMed ID: 33413149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravascular ultrasound assessment of optimal stent area to prevent in-stent restenosis after zotarolimus-, everolimus-, and sirolimus-eluting stent implantation.
    Song HG; Kang SJ; Ahn JM; Kim WJ; Lee JY; Park DW; Lee SW; Kim YH; Lee CW; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2014 May; 83(6):873-8. PubMed ID: 22815193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of serum apoA-I with in-stent restenosis in coronary heart disease.
    Wang X; Zhang M; Cheng J; Zhou H
    BMC Cardiovasc Disord; 2022 Aug; 22(1):355. PubMed ID: 35927634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simple balloon dilation for drug-eluting in-stent restenosis: an optical coherent tomography analysis.
    Arikawa R; Yamaguchi H; Takaoka J; Miyamura A; Atsuchi N; Ninomiya T; Atsuchi Y; Ohishi M; Terashima M; Kaneda H
    Cardiovasc Revasc Med; 2015; 16(1):27-31. PubMed ID: 25578507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-target lesion progression: Unveiling critical predictors and outcomes in patients with in-stent restenosis.
    Zhang W; Zhang W; Deng Y; Gu N; Qiu Z; Deng C; Yang S; Pan L; Long S; Wang Y; Zhao Y; Shi B
    Int J Cardiol; 2024 Dec; 416():132451. PubMed ID: 39147280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.
    Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Melgares R; Mainar V; Moreno R; Domínguez A; Sanchís J; Bethencourt A; Moreu J; Cequier A; Martí V; Otaegui I; Bastante T; Gonzalo N; Jiménez-Quevedo P; Cárdenas A; Fernández C;
    Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.